Approved Products and Development Pipeline
* Click here for JUXTAPID® (lomitapide) full prescribing information, including boxed warning for the risk of hepatotoxicity.
** Click here for MYALEPT® (metreleptin) full prescribing information, including boxed warning for the risk of anti-metreleptin antibodies with neutralizing activity and risk of lymphoma.
Our Pipeline: Status of Selected Key Development Programs as of October 2018
Represents current phase1 of development; does not correspond to initiation or completion of a particular phase1.
*** The ability to pursue these clinical development activities, and to conduct a clinical trial of metreleptin in PL if required by FDA in order to seek approval of PL in the U.S., will require additional funding, which may not be available. Additional funding is largely dependent upon effecting a refinancing of Aegerion's significant debt, or other wholesale recapitalization or other strategic alternative (any of which could cause Novelion and/or Aegerion to use the protection of the bankruptcy code to effectuate such alternative), or other product transaction, such as a territory licensing deal, and we may not been successful in doing so.
Drug development and commercialization involve significant and inherent risks. Please refer to the risk factors in our most recent Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission (SEC), and updates to such risk factors in subsequent SEC filings.
1 Data on file